Stock screenerAll disclosures →
EDGAR →
GILD
Conviction 76HealthcareScan · Tue, Sep 8, 2026Gravestone doji
GILD$146.64-2.88%
ResistanceSupportVol 14Insider sellCongress buyCongress sell3
4
5
3
2
Vol MA14 5.47M
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
WSB mentions · 24h changelatest +0.00%· 1 mentions
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
Price146.64
Change-2.88%
Gap-2.94%
Rel volume0.96×
Avg volume5.29M
Avg $ vol767.49M
SMA 20145.03
SMA 50136.98
SMA 200134.46
Price vs 50+7.05%
Price vs 200+9.06%
MA stackbullish
50/200 crossgolden · 7d
Supertrendup · 139.62
RSI (14)57
MACD hist-0.09
MACD crossbear · 0d
Stoch %K / %D37 / 72
ADX (14)39
+DI / −DI27 / 17
RSI divergence—
MACD divergence—
ATR %+2.56%
ADR %2.35%
52w high155.80
52w low110.56
From 52w high-5.88%
Above 52w low+32.63%
New 52w highNo
SqueezeOff
Bollinger width13.46%
%B0.58
Donchian pos71.23%
Donchian high152.55
Donchian low132.01
AVWAP (52w high)136.14
vs AVWAP high+7.72%
AVWAP (52w low)131.88
vs AVWAP low+11.19%
OBV trendUp
Chaikin MF (20)0.38
Today vs 20d0.96×
Avg vol (14d)5.47M
Avg vol (20d)5.29M
Avg $ vol (20d)767.49M
Market cap181.83B
RS 3m (vs SPY)+12.48%
RS 6m (vs SPY)-9.64%
RS line new highYes
Trend template7/8
Technical rank63.1
1 week+0.21%
1 month+10.08%
3 months+14.47%
6 months+0.01%
1 year+27.46%
YTD+20.59%
P/E21.37
P/B15.37
P/S6.18
P/FCF19.23
EPS6.78
Div yield2.20%
ROE71.94%
ROA17.24%
Debt/Eq2.22
Current1.27
EV/EBITDA—
Gross margin20.14%
Net margin28.90%
Rev growth2.40%
EPS growth1672.92%
Price target158.05
Target upside7.78%
Analyst ratingBuy
Institutional100.30%
Ent. value202.66B
Revenue7.8B
Net income-10.5B
Gross profit—
Free cash flow9.46B
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out1.24B
Employees17K
ListedWed, Jan 22, 1992
Free float1.24B
Float %99.7%
Short interest23.18M
Days to cover3.2d
Short volume37.2%
Squeeze score20 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$6.75 vs −$7.07
Last surprise+4.5% beat
Setup gradeA
Conviction76 / 100
Pattern quality—
Tech rank63.1 / 100
Group rank96 / 100 · Leading
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmGravestone doji
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Signal lifecycle
How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.
- Setting upAug 10 – Aug 123 scans
- Breaking out nowAug 141 scan
Recent news
- Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of MedicinesYahoo Finance · Tue, Sep 8, 2026
- Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market?Yahoo Finance · Tue, Sep 8, 2026
- IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?247Wallst · Mon, Sep 7, 2026
- Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ RivalsYahoo Finance · Mon, Sep 7, 2026
- Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?Motley Fool · Sat, Sep 5, 2026
- Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?Yahoo Finance · Fri, Sep 4, 2026
- Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?Yahoo Finance · Fri, Sep 4, 2026
- Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?247Wallst · Fri, Sep 4, 2026
- Gilead’s growing HIV franchise; cell therapy licensing deals plummetPharmavoice · Fri, Sep 4, 2026
Congress activity
Disclosed STOCK Act trades in GILD · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Thomas H Tuberville senate · traded 2024-05-10 | Buy | $1K–$15K | 2024-05-10 | 2026-08-05 | |
Thomas H Tuberville senate · traded 2024-05-08 | Sell | $1K–$15K | 2024-05-08 | 2026-08-05 | |
 Alan Armstrong senate · R · OK · traded 2026-03-27 | Buy | $1K–$15K | 2026-03-27 | 2026-07-21 | |
 Jared Moskowitz house · D · FL · traded 2026-05-06 | Buy | $1K–$15K | 2026-05-06 | 2026-06-19 | |
 Josh Gottheimer house · D · NJ · traded 2026-01-27 | Buy | $1K–$15K | 2026-01-27 | 2026-02-26 | |
 Valerie Hoyle house · D · OR · traded 2025-09-23 | Sell | $1K–$15K | 2025-09-23 | 2025-10-10 | |
Valerie Hoyle house · D · OR · traded 2024-10-29 | Buy | $1K–$15K | 2024-10-29 | 2025-09-12 | |
 Jefferson Shreve house · R · IN · traded 2025-05-12 | Sell | $15K–$50K | 2025-05-12 | 2025-06-22 | |
 Marjorie Taylor Greene house · GA · traded 2025-06-06 | Buy | $1K–$15K | 2025-06-06 | 2025-06-18 | |
Josh Gottheimer house · D · NJ · traded 2025-05-14 | Sell | $1K–$15K | 2025-05-14 | 2025-06-11 |
Insider activity
SEC Form 4 transactions in GILD · 2 buys · 8 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-09-01 | Sell | 1.6K | $236K | 2026-09-01 | 2026-09-02 |
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-09-01 | Sell | 7.99K | $1.2M | 2026-09-01 | 2026-09-02 |
O'Day Daniel Patrick Chairman & CEO · Common Stock · 2026-09-01 | Sell | 5.41K | $808K | 2026-09-01 | 2026-09-02 |
WELTERS ANTHONY Director · Common Stock · 2026-08-26 | Exercise | 7.72K | $468K | 2026-08-26 | 2026-08-27 |
WELTERS ANTHONY Director · Common Stock · 2026-08-26 | Sell | 3.12K | $462K | 2026-08-26 | 2026-08-27 |
WELTERS ANTHONY Director · Common Stock · 2026-08-26 | Sell | 4.6K | $685K | 2026-08-26 | 2026-08-27 |
WELTERS ANTHONY Director · Common Stock · 2026-08-26 | Exercise | 10.28K | $631K | 2026-08-26 | 2026-08-27 |
WELTERS ANTHONY Director · Common Stock · 2026-08-26 | Sell | 3.4K | $504K | 2026-08-26 | 2026-08-27 |
WELTERS ANTHONY Director · Common Stock · 2026-08-26 | Sell | 6.88K | $1.0M | 2026-08-26 | 2026-08-27 |
WELTERS ANTHONY Director · Non-qualified Stock Option (Right to Buy) · 2026-08-26 | Exercise | 7.72K | — | 2026-08-26 | 2026-08-27 |
SEC filings
EDGAR filings in GILD · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.